The process of drug discovery involves the study of the pharmacokinetics (PK) properties of new drug candidates. While in vitro ADME (Absorption, Distribution, Metabolism and Excretion) assays provide valuable information on new drug candidates, it is important to interpret and extrapolate any data generated to in vivo situations using preclinical in vivo PK studies. NoAb BioDiscoveries (www.noabbiodiscoveries.com) is one of North America's leading providers of preclinical in vivo PK studies in addition to in vitro ADME assays, bioanalytical services and gene expression assays. The contract research organization (CRO) is located in one of the key biotech hubs and houses state-of-the-art equipment and a team of experienced scientists that bring to the forefront, exceptional research services. These research services focus on lead selection and optimization.
Using the information generated from the preclinical in vivo PK studies, in vitro ADME assays and other discovery services, clients are afforded the ability to profile compounds for the selection of the best candidates for further preclinical and clinical development. Using advanced research tools, the selection of viable clinical candidates is optimized based on the better characterization of their PK properties. The preclinical in vivo PK studies at NoAb BioDiscoveries include studies in carotid and jugular vein catheterized rats with intra-duodenal dosing, carotid artery, jugular vein and bile duct catheterized rats and guinea pigs, hepatoportal vein catheterized rats, serial collection of plasma and cerebrospinal fluid (CSF) from freely moving rats and microdialysis. The scientists skillfully design and perform standard and specialized protocols such as CSF collection and microdialysis according to customer specifications. The team of experienced scientists has the capability to design the best strategies and protocols for any drug discovery design.
All preclinical in vivo PK studies are carried out in-house under strict guidelines in a government approved vivarium that houses small rodents including rats and mice. Though the guidelines followed are not GLP guidelines, the animals are still handled in the same spirit and with proper controls. Highly trained and experienced scientists carry out the preclinical in vivo PK studies on fully conscious animals that have been appropriately catheterized for drug administration and sample collection and ensure quality, efficiency and timeliness. NoAb BioDiscoveries' range of discovery services are all highly efficient and of high quality due to constant innovation from the organization. These innovative tools and technologies help to achieve success and accelerate the timelines associated with selecting and optimizing viable clinical candidates while the superior scientific procedures ensure that the results obtained are accurate and reliable.
When you choose preclinical in vivo PK studies and other drug discovery services from NoAb BioDiscoveries, you reduce the cost to identify and market new drugs while maximizing your success. The drug discovery market is a very competitive one as pharmaceutical developers strive to keep up with the demand for new drugs but with NoAb BioDiscoveries as your trusted partner you can stay ahead of the competition! Let the team of experts design you the best strategies to select the best candidates for further preclinical and clinical development for any drug discovery needs.
